featured
5-Year Outcomes With Nivolumab vs Docetaxel in Previously Treated NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer
J. Clin. Oncol 2021 Jan 15;[EPub Ahead of Print], H Borghaei, S Gettinger, EE Vokes, LQM Chow, MA Burgio, J de Castro Carpeno, A Pluzanski, O Arrieta, OA Frontera, R Chiari, C Butts, J Wójcik-Tomaszewska, B Coudert, MC Garassino, N Ready, E Felip, MA García, D Waterhouse, M Domine, F Barlesi, S Antonia, M Wohlleber, DE Gerber, G Czyzewicz, DR Spigel, L Crino, WEE Eberhardt, A Li, S Marimuthu, J BrahmerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.